Crohn's Disease Clinical Trial Tracker — Monitor the IBD Pipeline

Why Crohn's disease trial monitoring matters

Inflammatory bowel disease — particularly Crohn's disease — is one of the most active therapeutic areas in immunology. The IBD pipeline has expanded dramatically with the validation of new targets like TL1A, the maturation of selective IL-23 inhibitors, and the emergence of oral small molecule approaches including JAK inhibitors and S1P receptor modulators.

For pharma BD teams, biotech investors, and gastroenterology researchers, the pace of IBD clinical development creates a significant monitoring challenge. Key signals to track:

• Anti-TL1A programs — the most competitive new target class in IBD following tulisokibart and duvakitug
• Selective IL-23 inhibitors (risankizumab, guselkumab, mirikizumab competitors)
• JAK inhibitor programs (selective JAK1, TYK2 inhibitors) addressing safety profile optimization
• S1P receptor modulators expanding from ulcerative colitis to Crohn's disease
• Combination therapy trials — biologics + small molecules, dual-mechanism approaches
• Biomarker-driven patient selection trials advancing precision medicine in IBD
• Pediatric Crohn's disease trials — a growing area of unmet need

What we monitor for Crohn's disease

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a Crohn's/IBD watch profile, you can configure:

• Condition keywords: "Crohn's disease", "Crohn disease", "inflammatory bowel disease", "IBD", "fistulizing Crohn's", "pediatric Crohn's"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The Crohn's disease treatment landscape in 2026

Anti-TL1A antibodies — the next blockbuster target

TL1A (TNF-like ligand 1A) has emerged as the most validated new target in IBD since anti-TNF therapy. Multiple programs from major pharma companies are racing through clinical development, with tulisokibart (Merck) and duvakitug (AbbVie/Teva) leading the way. Monitoring new TL1A trial registrations provides early competitive intelligence on this rapidly evolving space.

Next-generation IL-23 inhibition

Following the success of risankizumab (Skyrizi) in Crohn's disease, the IL-23 class is expanding with multiple agents in development. Competitive dynamics are intensifying as companies differentiate on dosing convenience, combination strategies, and head-to-head trial designs.

Oral small molecules

JAK inhibitors and S1P receptor modulators offer the appeal of oral dosing in a market dominated by injectable biologics. The challenge has been balancing efficacy with safety, and new-generation selective inhibitors aim to improve the therapeutic index. Tracking oral agent trials is essential for understanding the future competitive landscape.

Combination and sequencing trials

The IBD field is increasingly exploring combination approaches — pairing biologics with small molecules, or using sequential therapy strategies. These trials represent the frontier of Crohn's disease treatment and often signal where the field is headed.

Who uses Crohn's disease trial monitoring

Pharma immunology teams

Companies with IBD portfolios track competitor trial activity to inform development strategy, partnership decisions, and market access planning. A new Phase 3 program in moderate-to-severe Crohn's disease represents a future competitive entry that affects commercial planning.

Biotech investors

IBD has become one of the highest-value therapeutic markets globally. Investors track trial starts and phase transitions to identify catalysts, de-risk pipeline bets, and understand competitive positioning.

Gastroenterology researchers

Academic gastroenterologists and IBD researchers monitor new trial registrations to identify collaboration opportunities, refer patients to appropriate clinical trials, and stay current on emerging treatment approaches.

Patient advocacy organizations

Organizations like the Crohn's & Colitis Foundation track recruiting trials to help patients access new treatment options through clinical trial participation.

Frequently asked questions

How current is the Crohn's disease trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track Crohn's disease and ulcerative colitis together?

Yes. You can create a broader "IBD" profile that covers both Crohn's disease and ulcerative colitis, or separate profiles for each. On the Pro plan ($129/month), you can create up to 5 search profiles.

Does this cover international IBD trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — international Crohn's disease trials registered on ClinicalTrials.gov are included.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS-style alerts without phase filtering, sponsor type filtering, or organized digest formatting. We provide filtered, labeled, and organized alerts — the intelligence layer on top of the raw registry data.